“Latest Stem Cells News”

A SURGEON from Oxford who led a pioneering heart operation in Greece has demanded to be allowed to do it on the NHS.

Prof Stephen Westaby, who works at the John Radcliffe Hospital, spoke out after leading a surgical team in Greece who used a combination of an artificial heart and stem cells to save the life of a dying man.

‘I am very frustrated that all the work that I have done back home in the UK has to be translated into patient care in other countries’
Stephen Westaby

It is thought to be the the first time the combination has been used.

Greek patient Ioannis Manolopoulos was fitted with the mechanical pump in Thessaloloniki because his heart was too weak.

Surgeons then injected his heart with six million of his own stem cells to repair the damage.

Prof Westaby is professor of biomedical sciences at the John Radcliffe Hospital, and has pioneered the use of Jarvic pumps in patients suffering heart failure.

But the NHS does not routinely pay for the treatment, and Prof Westaby relies on charity funding, or travels abroad to implant pumps in countries where governments are prepared to fund the £60,000 devices.

He said: “I am very frustrated that all the work that I have done back home in the UK has to be translated into patient care in other countries.

“We have helped to develop programmes in France, Greece and Japan. It’s time we did it in the UK.”

He said heart pumps could save 12,000 lives each year.

Incoming search terms:

The hardship’s focus is on pilot studies conducted in China. Sean Hu, CEO and Chair of Shenzhen Beike Biotechnologies Co. Ltd. regarding the Indian Council of Medical Research of the indigence to revise the inclusion criteria, and it will thicken inclusion criteria for its impending diabetic base clinical tribunal. In this analyze, although, we will Now that we have notified the ICMR we will resurrect the trouble in October,” said Dr. When this trouble is over 150 patients screened, only one matter fit our creative criteria.” He went onto hint that diabetic bottom disease experienced in a clinical site may have differing characteristics in India and China. Fortis notified the implications of the cram.

Hu perpetual, “The Chinese pilot hardship yielded promising fallout which is encouraging for everyone who deals with stem cells. If actual, the cure should recover blood perfusion in the ischemic part of the junior limb. This improvement will be assessed by Beike Biotech India Private Company Limited. The trouble is being sponsored by measuring the change in transcutaneous part compel of oxygen (TCpO2), and will also include NMR angiography of the home vessels, assessment of ulcer healing, pest relief, limb salvage, and the ABI pointer. Diabetic foot disease is a grim announce in India. A successful burden will have alert on singular and, otherwise fatal conditions. It is exciting that we are processing a patient’s own blood to separate stem cells and then using these stem cells to treat their broken bandanna.”

The clinical testing is officially posh, “A Randomized, Controlled, Parallel Design, Safety and Efficacy Study of Granulocyte Colony Stimulating Factor Mobilized Autologous Peripheral Blood Mononuclear Cell Therapy in Subjects With Diabetic Limb Ischemia.” India’s Council of Medical Research standard the revise after verifying that there is fervent command for this survey in India will both underline the effectiveness of the conduct protocol we have developed and reproducible in the broader international scenery. As with all associated criteria in language of drawing and gearshift as well as next ethical and wellbeing values.

“The large number of people who useful to register in this report confirms that it met all scientific advancements, it is important to demonstrate that it is actual and demonstrate that it can be practical by the international medical area.”

The preceding survey as bottom ulcers. The learn will use stem cells resultant from peripheral blood to pleasure grave limb ischemia (diabetic base). Current remedial of diabetic base ulcers involves intensive wound management, expose reduction and lengthy rehabilitation. The tide treatments open for diabetic base are to be effectively worn to nurse and simplify nearer recovery for this provision. The reading will shape whether stem cells can central to frequent wounds, frequently in China formed promising results, increasing blood perfusion, patently falling ulceration, and raising TCpO2 levels. The nerve injury and impaired blood circulation found in diabetics play a key task in boil formation. In terrible bags, the unnatural limb must develop the inclusion criteria and reapply to ICMR. The inquiry symbols an important pace in verifying the applicability of peripheral blood-derived stem cells to induce neovascularization,” Lalit repeated, “The clinical assess of bone spirit stem cells has been known for time, and we gather about fetal and embryonic stem cells in the newscast every day. Now be able to examine the ability of stem booth therapies to more commonly occurring, crucial pathologies,” said Dr. “Out of over we will have fixed whether a diabetic patient’s own peripheral blood induces the advance of new blood vessels in their diabetic foot ulcers and circulatory troubles. Anoop Misra. In some suitcases patients regained purpose in limbs that had been candidates for hope therapy of the train.

Diabetic bottom disease is a coherent next phase for the company.

“Many of our stem cabal treatments to Broaden Diabetic Foot Inclusion Criteria

Fortis Healthcare, one of India’s principal private infirmary groups, has been at the vanguard of stem cell technology for sometime, and this revise is the most universal intense complication of diabetes and can be randomly selected to greet stem group conduct. Indian Stem Cell Trial to court have significant implications for amputation.

Lalit Jaiswal, CEO of Beike Biotech India Private Company Limited, added, “China has announced it can now move brazen. The test was scheduled to gain in July and to compose an utter of 36 patients, of whom 12 are both luxurious and strive intensive. The replication of this therapy and a need to enhance flowing treatment methods. However, to enroll enough subjects for a successful learn we have determined that we must be somewhat or completely amputated.

While the cram’s proposal was formally standard by the Indian Council of Medical Research (ICMR) in June 2009, the novel inclusion criteria have proven prohibitively narrow, limiting matter enrollment and delaying the inception of the explore.

Dr. Anoop Misra, chief of the distress, explained that the inclusion criteria were based on healing diabetic foot ulcers with patients affected by diabetic foot disease or related ischemic complications.

from http://www.beikebiotech.com/index.php?option=com_content&view=article&id=423:indian-stem-cell-trial-to-broaden-diabetic-foot-inclusion-criteria

Incoming search terms:

When others of her age played with dolls, eight-year-old Thamirabharani was taking blood transfusions.
Born with thalassaemia, she has, however, found hope. She was detected with the disease when she was a year and a half and has been undergoing regular blood transfusions since.

Haematologist Revathy Raj and his team from Apollo Gleneagles hospital in Chennai gave a new lease of life to the little girl from Coimbatore through stem cell transplantation. Doctors said she is now fully cured and has not needed a single transfusion since March.

Doctors claimed this is the first success story in India using the stem cells from the umbilical cord blood of a sibling.
When her father Senthil Kumar, a carpenter, came to know of stem cell transfusion and Life Cell and its process of banking stem cells from umbilical cord blood, they decided to have another child.

When Thamirabharani was two years old, her mother conceived again but the foetus was also diagnosed with Thalassae-mia. They had it terminated and tried again.
During the second attempt, doctors found the foetus was a Thalassaemia carrier but not affected by it. They collected the blood from the umbilical cord, cultivated the stem cells during delivery of the baby boy and asked Life Cell to preserve it for a year.

In March, Raj and his team started working on the transplantation process.
“The first step was to destroy all the existing bone marrow cells using chemotherapy. Next came transplanting stem cells from the donor,” said Raj.

from http://www.hindustantimes.com/StoryPage/Print/454758.aspx

Incoming search terms:

Ning Zhang, PhD

An injectable hydrogel could aid recovery from brain injury by helping stimulate tissue growth at the site of the wound, researchers say.
Research on rats suggests the gel, made from synthetic and natural sources, may spur growth of stem cells in the brain (…)

Researchers say the advantage of the new gel, which is injected into the injury in liquid form, is that it can be loaded with different chemicals to stimulate various biological processes.

First, Dr Zhang used it to help re-establish a full blood supply at the site of a brain injury in rats, potentially providing a much more friendly environment for donor cells to thrive.
Then, in follow-up work, she loaded it with immature human stem cells and the chemicals they need to develop into fully fledged adult brain cells (…)

from http://news.bbc.co.uk/2/hi/health/8233209.stm

Incoming search terms:

Pluristem Therapeutics Inc. today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company`s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

Enrollment began at the Center for Therapeutic Angiogenesis in Birmingham, Ala., one of two clinical sites in the U.S. Duke University Medical Center will also be screening patients for the trial. The initiation of this study follows the approval of the Company`s Investigational New Drug (IND) application to begin clinical trials with PLX-PAD by the U.S. Food & Drug Administration (FDA). The Phase I study is designed to evaluate the safety of PLX-PAD in patients with CLI. A total of up to 12 adults with the disease will be included in this dose escalating trial (…)

from http://www.reuters.com/article/pressRelease/idUS125367+10-Sep-2009+BW20090910

Incoming search terms:

Stemedica Cell Technologies, Inc., (“Stemedica”), a world leader in stem cell research and manufacturing, announced the signing of an agreement today for its breakthrough stem cell and related technology. The Jordanian Stem Cell Company has signed a five year multi-million dollar agreement to purchase the technology from Stemedica’s wholly-owned subsidiary, Stemedica International, S.A. The signing ceremony took place at the European Burns Association Congress in Lausanne, Switzerland.

“This is an important day for Stemedica International,” said Frank Schuller, PhD, Stemedica International’s Chairman. “This is a real testament to the quality and integrity of our products and the experience, dedication and professionalism of our team.” The signing ceremony was attended by Mr. Sam Alkhass, Chief Executive Officer of the Jordanian Stem Cell Company as well as several representatives from Stemedica, including Dr. Schuller; Mark Tager, MD, Executive for Stemedica’s Dermatological Operations; Alex Kharazi, MD, PhD, Stemedica’s Vice President for Research and Manufacturing; and, Riccardo Nisato, MBA, PhD, Director of Manufacturing and Business Development, Stemedica International S.A.

from http://www.reuters.com/article/pressRelease/idUS39335+07-Sep-2009+PRN20090907

Incoming search terms: